Danaher Corporation

XTRA:DAP Stock Report

Market Cap: €160.6b

Danaher Valuation

Is DAP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DAP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DAP (€220.85) is trading below our estimate of fair value (€228.5)

Significantly Below Fair Value: DAP is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DAP?

Key metric: As DAP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DAP. This is calculated by dividing DAP's market cap by their current earnings.
What is DAP's PE Ratio?
PE Ratio43.2x
EarningsUS$3.93b
Market CapUS$168.36b

Price to Earnings Ratio vs Peers

How does DAP's PE Ratio compare to its peers?

The above table shows the PE ratio for DAP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average63.1x
SRT3 Sartorius
182.4x36.4%€12.8b
1SXP SCHOTT Pharma KGaA
26.3x15.9%€3.9b
GXI Gerresheimer
21.3x21.7%€2.4b
MRK Merck KGaA
22.3x10.7%€60.1b
DAP Danaher
43.2x14.0%€168.4b

Price-To-Earnings vs Peers: DAP is good value based on its Price-To-Earnings Ratio (43.2x) compared to the peer average (63.1x).

Price to Earnings Ratio vs Industry

How does DAP's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
DAP 43.2xIndustry Avg. 37.4xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DAP is expensive based on its Price-To-Earnings Ratio (43.2x) compared to the European Life Sciences industry average (37.6x).

Price to Earnings Ratio vs Fair Ratio

What is DAP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DAP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.2x
Fair PE Ratio26.2x

Price-To-Earnings vs Fair Ratio: DAP is expensive based on its Price-To-Earnings Ratio (43.2x) compared to the estimated Fair Price-To-Earnings Ratio (26.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DAP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€220.85
€275.27
+24.6%
5.7%€298.87€241.94n/a24
Nov ’25€229.05
€266.40
+16.3%
5.9%€289.61€234.45n/a24
Oct ’25€248.60
€261.40
+5.1%
7.1%€300.83€225.85n/a23
Sep ’25€241.25
€255.59
+5.9%
6.4%€277.17€223.53n/a22
Aug ’25€258.55
€265.17
+2.6%
6.5%€287.28€231.68n/a21
Jul ’25€229.00
€250.83
+9.5%
7.6%€275.25€201.85n/a23
Jun ’25€235.45
€254.28
+8.0%
7.5%€279.66€205.08n/a23
May ’25€230.75
€251.90
+9.2%
8.8%€279.81€194.00n/a24
Apr ’25€231.20
€242.17
+4.7%
9.1%€277.11€192.13n/a24
Mar ’25€234.40
€241.90
+3.2%
9.3%€278.31€192.96n/a24
Feb ’25€222.60
€240.94
+8.2%
9.3%€277.65€192.50n/a24
Jan ’25€210.30
€223.88
+6.5%
10.3%€277.17€185.69n/a25
Dec ’24€204.70
€225.24
+10.0%
10.3%€285.38€193.98n/a23
Nov ’24€180.30
€228.31
+26.6%
10.6%€288.22€195.92€229.0523
Oct ’24€235.70
€269.94
+14.5%
5.4%€291.28€228.46€248.6023
Sep ’24€246.70
€260.03
+5.4%
6.2%€297.60€219.77€241.2524
Aug ’24€232.00
€258.56
+11.4%
6.8%€297.53€217.70€258.5522
Jul ’24€220.20
€259.31
+17.8%
9.0%€331.36€232.70€229.0022
Jun ’24€215.90
€261.53
+21.1%
8.8%€333.11€233.93€235.4522
May ’24€215.10
€257.82
+19.9%
9.7%€324.49€220.58€230.7521
Apr ’24€231.75
€284.36
+22.7%
8.2%€343.28€227.60€231.2020
Mar ’24€230.85
€278.71
+20.7%
8.2%€335.91€222.71€234.4020
Feb ’24€244.15
€278.71
+14.2%
8.2%€335.91€222.71€222.6020
Jan ’24€248.50
€287.22
+15.6%
8.0%€322.37€228.11€210.3021
Dec ’23€260.55
€290.35
+11.4%
8.2%€324.90€229.90€204.7019
Nov ’23€257.20
€310.66
+20.8%
9.5%€346.75€217.99€180.3020

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

0.7%

1Y

20.2%